NCT02535247 · OUTCOME

Progression Free Survival

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma · Source last updated 2022-07-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 3 Months

What was measured

Based on RECIST v1.1

Analysis population: Some patients unevaluable for PFS

Groups in this outcome

Treatment

MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles MK-3475

Combination

MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study MK-3475 Copanlisib

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment	11
Combination	0

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment	6	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
6

denoms

counts
group Id
OG000
value
11
group Id
OG001
value
0
units
Participants

description

Based on RECIST v1.1

groups

description
MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles MK-3475
id
OG000
title
Treatment
description
MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study MK-3475 Copanlisib
id
OG001
title
Combination

param Type

COUNT_OF_PARTICIPANTS

population Description

Some patients unevaluable for PFS

reporting Status

POSTED

time Frame

3 Months

title

Progression Free Survival

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice